IL-6 serum levels have been associated with high risk of poor prognosis in patients with severe COVID-19 so, guiding tocilizumab treatment according to the levels of IL-6 could be a strategy to maximize outcomes, and optimize the proper use of a limited and expensive resource. Here, IL6 is linked to COVID-19.